8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 15, 2005)

Filed February 15, 2005For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 15, 2005, to report its financial results for the fourth quarter and full year ended December 31, 2004. This filing primarily serves to furnish the accompanying press release detailing these financial outcomes. While the filing itself does not contain extensive commentary, the attached press release (Exhibit 99.1) is the key document for investors seeking to understand the company's financial performance and position as of that date. Investors should focus on the financial data and operational highlights provided in the press release, which will offer insights into revenue, expenses, net loss, and cash position. As a company in the biotechnology sector at that time, the results likely reflect ongoing research and development activities, clinical trial progress, and potential strategic partnerships. Understanding these elements is crucial for assessing Alnylam's progress and future prospects.

Key Highlights

  • 1Filing of an 8-K report on February 15, 2005, by Alnylam Pharmaceuticals, Inc.
  • 2The report announces financial results for the fourth quarter and full year ended December 31, 2004.
  • 3The primary purpose of the filing is to furnish a press release (Exhibit 99.1) containing these financial results.
  • 4The press release serves as the main source of detailed financial and operational information for investors.
  • 5The filing notes that the information furnished is not deemed 'filed' for Section 18 of the Exchange Act purposes.
  • 6John M. Maraganore, Ph.D., President and CEO, signed the report.
  • 7The company is incorporated in Delaware and its principal executive offices are located in Cambridge, MA.

Frequently Asked Questions

The main purpose of this Form 8-K filing is to announce and provide Alnylam Pharmaceuticals, Inc.'s financial results for the fourth quarter and the full fiscal year ended December 31, 2004, by furnishing a press release.

The detailed financial results and operational information are contained within the press release, filed as Exhibit 99.1 to this Form 8-K.

No, the information in this Form 8-K, including the furnished press release, is specifically stated as not being 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to its liabilities, unless expressly incorporated by reference in another filing.

The report was signed by John M. Maraganore, Ph.D., who is the President and Chief Executive Officer of Alnylam Pharmaceuticals, Inc.